๐ฐ Jun Ma News
Page 4 - Jun Ma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Jun Ma. Real-time updates on events, politics, business and more.
May 18, 2023
A recent study found that an AI voice assistant app in aiding patients with mild depression and anxiety.
May 17, 2023
A study found changes in patients brain activity along with improved depression and anxiety symptoms after using Lumen.
April 5, 2023
Lithium-ion batteries are utilized in a variety of applications, including not only small consumer electronics such as cell phones and laptop computers, but also electric vehicles, electric bicycles, and long-term power storage.
April 4, 2023
Methane makes up 99.5% of the combustible ice, making it a vital reserve energy source. The reserves of combustible ice in the South China Sea are estimated to be at least 80 billion tons of oil equivalent.
March 29, 2023
The Company Announces Record Annual Revenue and ProfitPLAINVIEW, NY / ACCESSWIRE / March 29, 2023 / Vaso Corporation ("Vaso") (OTCQB:VASO) today announced its operating results for the three months and
March 29, 2023
CORRECTION FROM SOURCE: Vaso Corporation Announces Financial Results ...
February 22, 2023
BUFFALO, N.Y. (PRWEB) February 21, 2023 -- ยท Few prior studies have evaluated how socioeconomic status affects tumor biologyยท Observational study included
February 21, 2023
Patients with early-stage estrogen receptor-positive breast cancer who live in low-income neighborhoods are likelier to have more-aggressive tumors and significantly lower overall survival (OS) than those in higher-income neighborhoods, according to research led by Roswell Park Comprehensive Cancer Center.
December 12, 2022
Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting - read this article along with other careers information, tips and advice on BioSpace
December 11, 2022
Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting